Xinhua News Agency, Beijing, June 25th: Summary: WHO certified data is full-China’s new crown vaccine helps the global fight against the epidemic
Xinhua News Agency reporter
The new crown epidemic has been raging for more than a year, and the increased spread of the mutant new crown virus has brought new challenges to the global fight against the epidemic. Vaccines are a powerful weapon to deal with the epidemic and help the world build an immune barrier as soon as possible. China has been working hard to contribute to improving the accessibility and affordability of vaccines in developing countries. So far, it has provided more than 350 million doses of COVID-19 vaccine to the international community.
With the gradual expansion of the scale of Chinese vaccines in many countries around the world, more and more research data show the safety and effectiveness of Chinese vaccines. Since May, the two new crown vaccines of Sinopharm and Kexing have been included in the emergency use list of the World Health Organization, which has contributed to China’s efforts to alleviate the unfair distribution of global vaccines and help the global fight against the epidemic.
The WHO announced on May 7 that the new crown inactivated vaccine developed by the Beijing Institute of Biological Products of China National Pharmaceutical Group has officially passed the WHO emergency use certification. This is the sixth new coronavirus vaccine in the world that has been validated by WHO for its safety, effectiveness and quality. According to data approved by the WHO Immunization Strategy Advisory Panel, the vaccine’s effectiveness for symptomatic and hospitalized patients is estimated to be 79%.
On May 26, the mid-term results of the Phase III clinical trial of Sinopharm’s new crown vaccine were officially published in the Journal of the American Medical Association. Studies have shown that the protective efficacy of its two inactivated vaccines reached 72.8% and 78.1%, respectively. This is the world‘s first officially published Phase III clinical trial result of the new crown inactivated vaccine.
On June 1st, another Chinese vaccine, the new inactivated vaccine “Kierlefor” developed by China Beijing Kexing Zhongwei Biotechnology Co., Ltd., officially passed the WHO emergency use certification. The data shows that the vaccine has an effective rate of 51% in preventing the appearance of new coronary symptoms, and the effective rate of preventing severe new coronary diseases and hospitalization is 100%. WHO Director-General Tedros Adhanom Ghebreyesus said that the Koxing vaccine has proven to be “safe, effective and quality-assured.”
The easy storage of China’s new crown vaccine makes it very suitable for resource-poor environments. The website of the British “Nature” magazine once stated that China’s vaccine will help fill the current supply gap in the “New Coronary Pneumonia Vaccine Implementation Plan” and enable low-income countries to achieve large-scale vaccine distribution. The article specifically pointed out that for many countries and regions, the Chinese vaccine is the only vaccine available. In Brazil, Chile and other countries where Chinese vaccines are being vaccinated, local researchers have seen the effectiveness of these vaccines in controlling the epidemic.
At the end of May, the government of the State of Sao Paulo, Brazil, announced the results of a comprehensive vaccination trial of Coxing Vaccine in Serana City. Compared with the data at the beginning of the trial, after the full vaccination is completed, the number of new symptomatic new coronary cases in the local area has dropped by 80%, the number of hospitalizations has dropped by 86%, and the number of new deaths has dropped by 95%. Another important conclusion of the experiment comes from the contrast between the epidemic situation in Serana and surrounding cities. About 10,000 citizens of Serana work in the neighboring city of Ribeirao Preto. While the epidemic in Ribeirão Preto and other surrounding cities is still serious, the epidemic in Serana has been greatly eased.
The Federal University of Pelotas in Brazil announced in June the results of a joint study between the school and Harvard University in the United States: Thanks to the large-scale vaccination of the new crown vaccine, in the first five months of this year, more than 43,000 elderly people aged 70 and over in Brazil avoided Died from the new crown infection. Researchers believe that this result proves the effectiveness of the Chinese Coxing vaccine and the British AstraZeneca vaccine that were vaccinated in Brazil, and they are also effective against the gamma strain of the mutant virus found in the Amazon state of Brazil.
In mid-May, the Chilean Ministry of Health updated the protective effect of Coxing vaccine in the country’s “real world study”: 14 days after the second dose, the vaccine has an effective rate of 65.3% in preventing symptomatic infections. The efficiency is 87%, the effective rate of preventing entry into the intensive care unit is 90.3%, and the effective rate of preventing death caused by infection is 86%. Araus, an adviser to the Chilean Ministry of Health who led the study, said that after months of follow-up, the data accumulated so far is “reliable and positive”, proving that despite the mutated new coronavirus epidemic, the Coxing vaccine still shows good results. Protection effect.
The results of a study released by the Indonesian Ministry of Health in May showed that the Koxing vaccine is 94% effective in preventing symptomatic infections among medical staff, and 96% effective in preventing them from being admitted to hospital for new crown infections, and preventing deaths caused by infections. The effective rate is 98%.
At the 74th World Health Assembly held in Geneva, Switzerland at the end of May, many countries thanked China for assisting their countries in fighting the new crown epidemic by donating vaccines, sending experts, and transferring technology. Gabon’s Permanent Representative to the United Nations Office in Geneva, Mireye Sara Nzenze, said that since Gabon started its new crown vaccination on March 23 this year, more than 11,000 people have been vaccinated with the Sinopharm vaccine donated by China. The representative of Niger said that thanks to the support of China and other countries, Niger has established an effective epidemic response mechanism, and the fight against the epidemic has achieved satisfactory results. (Notewriter: Zhang Xiaoru; Participating reporters: Liu Qu, Peng Qian, Zhang Jiawei, Gong Ruohan, Zhang Xiaoran, Yu Qianliang, Zheng Shibo, Ling Xin, Chen Wenxian, Li Jizhi, Chen Junxia, Fu Yiming)
.